CHEK1 and breast cancer: When analyzing expression of the associated gene products by immunohistochemistry in tissue specimens from premenopausal breast cancer patients randomized to either tamoxifen or no adjuvant treatment, we observed that over-expression of cortactin and FADD as well as downregulation of Chk1 was linked to CCND1 amplification.